Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme

References

• Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neuro Oncol 2015; 17 Suppl 4:iv1-62; PMID:26511214; http://dx.doi.org/10.1093/neuonc/nov189
   PubMed Web of Science ®Google Scholar
• Messaoudi K, Clavreul A, Lagarce F. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov Today 2015; 7(20):889-905; PMID:25744176; http://dx.doi.org/10.1016/j.drudis.2015.02.011
   Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90; PMID:8663110; http://dx.doi.org/10.1074/jbc.271.22.12687
   PubMed Web of Science ®Google Scholar
• Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets 2015; 1-15; 9(19):1171-1185; PMID:26004811; http://dx.doi.org/10.1517/14728222.2015.1049838
   Web of Science ®Google Scholar
• den Hollander MW, Gietema JA, de Jong S, Walenkamp AME, Reyners AKL, Oldenhuis CNAM, de Vries EGE. Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett 2013; 332:194-201; PMID:22531313; http://dx.doi.org/10.1016/j.canlet.2012.04.007
   PubMed Web of Science ®Google Scholar
• Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013; 32:1341-50; PMID:22580613; http://dx.doi.org/10.1038/onc.2012.164
   PubMed Web of Science ®Google Scholar
• Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schröter M, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386:517-21; PMID:9087414; http://dx.doi.org/10.1038/386517a0
   PubMed Web of Science ®Google Scholar
• McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 2013; 5:a008656; PMID:23545416; http://dx.doi.org/10.1101/cshperspect.a008656
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Reed JC. IAP family proteins—suppressors of apoptosis. Genes Dev 1999; 13:239-52; PMID:9990849; http://dx.doi.org/10.1101/gad.13.3.239
   PubMed Web of Science ®Google Scholar
• Unterkircher T, Cristofanon S, Vellanki SHK, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin K-M, Fulda S. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 2011; 17:4019-30; PMID:21525171; http://dx.doi.org/10.1158/1078-0432.CCR-11-0075
   PubMed Web of Science ®Google Scholar
• Bagci-Onder T, Du W, Figueiredo J-L, Martinez-Quintanilla J, Shah K. Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain 2015; 6:138:1710-1721; PMID:25564487; http://dx.doi.org/10.1093/brain/awv094
   PubMed Web of Science ®Google Scholar
• Finlay D, Richardson RD, Landberg LK, Howes AL, Vuori K. Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis. PLoS One 2010; 5:e13375; PMID:20967281; http://dx.doi.org/10.1371/journal.pone.0013375
   PubMedGoogle Scholar
• Yip KW, Mao X, Au PYB, Hedley DW, Chow S, Dalili S, Mocanu JD, Bastianutto C, Schimmer A, Liu F-F. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clin Cancer Res 2006; 12:5557-69; PMID:17000693; http://dx.doi.org/10.1158/1078-0432.CCR-06-0536
   PubMed Web of Science ®Google Scholar
• Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL, Halfmann R, Naidoo J, Wang L, Li L, et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol 2013; 9:84-9; PMID:23292651; http://dx.doi.org/10.1038/nchembio.1153
   PubMed Web of Science ®Google Scholar
• Denicolaï E, Baeza-Kallee N, Tchoghandjian A, Carré M, Colin C, Jiglaire CJ, Mercurio S, Beclin C, Figarella-Branger D. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. Oncotarget 2014; 5:10934-48; PMID:2540011; http://dx.doi.org/10.18632/oncotarget.2541
   PubMed Web of Science ®Google Scholar
• Taylor DJ, Parsons CE, Han H, Jayaraman A, Rege K. Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells. BMC Cancer 2011; 11:470; PMID:22044796; http://dx.doi.org/10.1186/1471-2407-11-470
   PubMed Web of Science ®Google Scholar
• Grandhi TSP, Potta T, Taylor DJ, Tian Y, Johnson RH, Meldrum DR, Rege K. Sensitizing cancer cells to TRAIL-induced death by micellar delivery of mitoxantrone. Nanomedicine (Lond) 2014; 9:1775-88; PMID:24195660; http://dx.doi.org/10.2217/nnm.13.125
   PubMed Web of Science ®Google Scholar
• Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014; 21:1350-64; PMID:24948009; http://dx.doi.org/10.1038/cdd.2014.81
   PubMed Web of Science ®Google Scholar
• Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007; 448:645-6; PMID:17687303; http://dx.doi.org/10.1038/448645a
   PubMed Web of Science ®Google Scholar
• Jin G, Wong STC. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 2014; 19:637-44; PMID:24239728; http://dx.doi.org/10.1016/j.drudis.2013.11.005
   PubMed Web of Science ®Google Scholar
• Jiang P, Mukthavaram R, Mukthavavam R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, et al. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med 2014; 12:13; PMID:24433351; http://dx.doi.org/10.1186/1479-5876-12-13
   PubMed Web of Science ®Google Scholar
• Lee B-S, Amano T, Wang HQ, Pantoja JL, Yoon CW, Hanson CJ, Amatya R, Yen A, Black KL, Yu JS. Reactive oxygen species responsive nanoprodrug to treat intracranial glioblastoma. ACS Nano 2013; 7:3061-77; PMID:23557138; http://dx.doi.org/10.1021/nn400347j
   PubMed Web of Science ®Google Scholar
• Hothi P, Martins TJ, Chen L, Deleyrolle L, Reynolds B, Foltz G. High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells Abstract: 2012; 3:1124-36; PMID:23165409; http://dx.doi.org/10.18632/oncotarget.707
   PubMedGoogle Scholar
• Wieland A, Trageser D, Gogolok S, Reinartz R, Höfer H, Keller M, Leinhaas A, Schelle R, Normann S, Klaas L, et al. Anticancer effects of niclosamide in human glioblastoma. Clin Cancer Res 2013; 19:4124-36; PMID:23908450; http://dx.doi.org/10.1158/1078-0432.CCR-12-2895
   PubMed Web of Science ®Google Scholar
• Iacob G, Dinca EB. Current data and strategy in glioblastoma multiforme. 2009; Nov 15; 2(4): 386–393; PMID:20108752
   PubMedGoogle Scholar
• Booth NL, Sayers TJ, Brooks AD, Thomas CL, Jacobsen K, Goncharova EI, McMahon JB, Henrich CJ. A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. Cancer Immunol Immunother 2009; 58:1229-44; PMID:19089423; http://dx.doi.org/10.1007/s00262-008-0637-8
   PubMed Web of Science ®Google Scholar
• Yoon N, Park MS, Peltier GC, Lee RH. Pre-activated human mesenchymal stromal cells in combination with doxorubicin synergistically enhance tumor-suppressive activity in mice. Cytotherapy 2015; 17(10):1332-41; PMID:26227206; http://dx.doi.org/10.1016/j.jcyt.2015.06.009
   PubMed Web of Science ®Google Scholar
• Vaculova A, Kaminskyy V, Jalalvand E, Surova O, Zhivotovsky B. Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Mol Cancer 2010; 9:87; PMID:20416058; http://dx.doi.org/10.1186/1476-4598-9-87
   PubMed Web of Science ®Google Scholar
• Jayasooriya RGPT, Choi YH, Hyun JW, Kim G-Y. Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs. Environ Toxicol Pharmacol 2014; 38:959-67; PMID:25461556; http://dx.doi.org/10.1016/j.etap.2014.10.012
   PubMed Web of Science ®Google Scholar
• Brooks AD, Sayers TJ. Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother 2005; 54:499-505; PMID:15614529; http://dx.doi.org/10.1007/s00262-004-0595-8
   PubMed Web of Science ®Google Scholar
• Frew AJ, Lindemann RK, Martin BP, Clarke CJP, Sharkey J, Anthony DA, Banks K-M, Haynes NM, Gangatirkar P, Stanley K, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 2008; 105:11317-22; PMID:18685088; http://dx.doi.org/10.1073/pnas.0801868105
   PubMed Web of Science ®Google Scholar
• Weiland T, Weiller M, Künstle G, Wendel A. Sensitization by 5-azacytidine toward death receptor-induced hepatic apoptosis. J Pharmacol Exp Ther 2009; 328:107-15; PMID:18829727; http://dx.doi.org/10.1124/jpet.108.143560
   PubMed Web of Science ®Google Scholar
• Ramp U, Mahotka C, Krieg A, Walczak H. Sensitivity to TRAIL / APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. 2000; 1127-36.
   Google Scholar
• Kang MR, Kang JS, Yang JW, Kim BG, Kim J-A, Jo YN, Lee K, Lee CW, Lee KH, Yun J, et al. Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines. Oncol Lett 2012; 3:113-8; PMID:22740865; http://dx.doi.org/10.3892/ol.2011.430
   PubMed Web of Science ®Google Scholar
• Kim J, Taylor D, Agrawal N, Wang H, Kim H, Han A, Rege K, Jayaraman A. A programmable microfluidic cell array for combinatorial drug screening. Lab Chip 2012; 12:1813-22; PMID:22456798; http://dx.doi.org/10.1039/c2lc21202a
   PubMed Web of Science ®Google Scholar
• Wang W, Gallant J-N, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, et al. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther 2011; 12:229-38; PMID:21725212; http://dx.doi.org/10.4161/cbt.12.3.17033
   PubMed Web of Science ®Google Scholar
• Badr CE, Wurdinger T, Tannous BA. Functional drug screening assay reveals potential glioma therapeutics. Assay Drug Dev Technol 2011; 9:281-9; PMID:21184646; http://dx.doi.org/10.1089/adt.2010.0324
   PubMed Web of Science ®Google Scholar
• Apoptosis F-AL, Krishnamoorthy B, Darnay B, Aggarwal B, Apoptosis AL, Dinh DH, Kouraklis G, Olivero WC, Gujrati M, Rao JS. Glioma Cells Deficient in Urokinase Plaminogen Activator Receptor Expression Are Susceptible to Tumor Necrosis Glioma Cells Deficient in Urokinase Plaminogen Activator Receptor Expression Are Susceptible to Tumor Necrosis Factor- ␣ -related. 2001; 4195-201.
   Google Scholar
• Yoon MJ, Kang YJ, Kim IY, Kim EH, Lee JA, Lim JH, Kwon TK, Choi KS. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis 2013; 34:1918-28; PMID:23615398; http://dx.doi.org/10.1093/carcin/bgt137
   PubMed Web of Science ®Google Scholar
• Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J, Chen J, Wen Z, Jiang X. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release 2011; 154:93-102; PMID:21609741; http://dx.doi.org/10.1016/j.jconrel.2011.05.008
   PubMed Web of Science ®Google Scholar
• Ciusani E, Croci D, Gelati M, Calatozzolo C, Sciacca F, Fumagalli L, Balzarotti M, Fariselli L, Boiardi A, Salmaggi A. In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. J Neurooncol 2005; 71:19-25; PMID:15719269; http://dx.doi.org/10.1007/s11060-004-9180-4
   PubMed Web of Science ®Google Scholar
• Badr CE, Wurdinger T, Nilsson J, Niers JM, Whalen M, Degterev A, Tannous BA. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. Neuro Oncol 2011; 13:1213-24; PMID:21757445; http://dx.doi.org/10.1093/neuonc/nor067
   PubMed Web of Science ®Google Scholar
• Morales JC, Ruiz-Magaña MJ, Carranza D, Ortiz-Ferrón G, Ruiz-Ruiz C. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis. Cancer Lett 2010; 297:91-100; PMID:20580868; http://dx.doi.org/10.1016/j.canlet.2010.04.029
   PubMed Web of Science ®Google Scholar
• Bagci-Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, Shah K. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. Oncogene 2012; 32:2818-2827; PMID:22824792; http://dx.doi.org/10.1038/onc.2012.304
   PubMed Web of Science ®Google Scholar
• Kim DR, Park M-Y, Lee C-S, Shim S-H, Yoon H-I, Lee JH, Sung M-W, Kim Y-S, Lee C-T. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. Cancer Gene Ther 2011; 18:467-77; PMID:21455254; http://dx.doi.org/10.1038/cgt.2011.11
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Chowdhary S, Potthast L, Prabhu A, Tsai Y-Y, Sarcar B, Kahali S, Brem S, Yu HM, Rojiani A, et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol 2012; 14:93-100; PMID:22028388; http://dx.doi.org/10.1093/neuonc/nor187
   PubMed Web of Science ®Google Scholar
• Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov 2008; 7:926-35; PMID:18948999; http://dx.doi.org/10.1038/nrd2682
   PubMed Web of Science ®Google Scholar
• Lee D-H, Lee CS, Kim D-W, Ae JE, Lee T-H. Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin. Anticancer Drugs 2014; 25:44-52; PMID:24045365; http://dx.doi.org/10.1097/CAD.0000000000000015
   PubMed Web of Science ®Google Scholar
• Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta 2013; 1833:3448-59; PMID:23770045; http://dx.doi.org/10.1016/j.bbamcr.2013.06.001
   PubMed Web of Science ®Google Scholar
• Zhou J, Atsina K-B, Himes BT, Strohbehn GW, Saltzman WM. Novel delivery strategies for glioblastoma. Cancer J 2012; 18:89-99; PMID:22290262; http://dx.doi.org/10.1097/PPO.0b013e318244d8ae
   PubMed Web of Science ®Google Scholar
• Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004; 63:S15-8; PMID:15623664; http://dx.doi.org/10.1212/WNL.63.12_suppl_6.S15
   PubMedGoogle Scholar
• Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Levin VA, Alfred Yung WK, McDonnell TJ. Characterization of p53 and p21 Functional Interactions in Glioma Cells en Route to Apoptosis. JNCI J Natl Cancer Inst 1997; 89:1036-44; PMID:9230885; http://dx.doi.org/10.1093/jnci/89.14.1036
   PubMed Web of Science ®Google Scholar
• Furnari FB, Lin H, Huang HS, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A 1997; 94:12479-84; PMID:9356475; http://dx.doi.org/10.1073/pnas.94.23.12479
   PubMed Web of Science ®Google Scholar
• Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther 2008; 7:3575-85; PMID:19001440; http://dx.doi.org/10.1158/1535-7163.MCT-08-0640
   PubMed Web of Science ®Google Scholar
• Adiguzel Z, Baykal AT, Kacar O, Yilmaz VT, Ulukaya E, Acilan C. Biochemical and proteomic analysis of a potential anticancer agent: Palladium(II) Saccharinate complex of terpyridine acting through double strand break formation. J Proteome Res 2014; 13:5240-9; PMID:25210790; http://dx.doi.org/10.1021/pr5006718
   PubMed Web of Science ®Google Scholar